RxDoctor Payments Data

Robert Debruin, MD

Internal Medicine · Folsom, CANPI 1073507786

Payments from drug & device makers

$9,696in general payments, 2019–2025

Across 452 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$836
  • AstraZeneca$609
  • GSK$562
  • Madrigal Pharmaceuticals$528
  • Amgen$502
  • plus $6K from 43 others

What the payments were for

  • Food & beverage$9,50598%
  • Education$1912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,696 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$636,663
Medicare patients
495
Services billed
40,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$134,029
JardianceEmpagliflozin86$103,658
JanuviaSitagliptin Phosphate31$45,632
TrulicityDulaglutide24$40,258
OzempicSemaglutide29$33,847
MyrbetriqMirabegron34$27,275
RybelsusSemaglutide28$26,946
XareltoRivaroxaban15$24,690
MounjaroTirzepatide23$24,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,067
Dexlansoprazole DrDexlansoprazole41$14,297
Repatha SureclickEvolocumab16$13,770
Pregabalin139$9,819
Atorvastatin Calcium581$7,103
SymbicortBudesonide/Formoterol Fumarate29$7,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$836$134,029122 claims
Boehringer IngelheimJardiance$294$103,65886 claims
Lilly USA, LLCTrulicity, Mounjaro$464$64,39347 claims
Novo NordiskOzempic, Rybelsus$439$60,79357 claims
MerckJanuvia$477$45,63231 claims
Astellas Pharma US IncMyrbetriq$213$27,27534 claims
GSKTrelegy Ellipta, Breo Ellipta$562$26,56330 claims
Johnson & JohnsonXarelto$353$24,69015 claims
AstraZenecaSymbicort$609$7,07129 claims
AbbVieSynthroid$1,064$5,67287 claims
Kowa Pharmaceuticals America, Inc.Bystolic$403$2,14212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →